Tumor-Derived Immunoglobulin Driven Resistance to anti-PD1/PDL1 Axis Therapy Grant

Tumor-Derived Immunoglobulin Driven Resistance to anti-PD1/PDL1 Axis Therapy .

date/time interval

  • September 21, 2023 - September 20, 2024

administered by

sponsor award ID

  • Agreement 9/21/23

contributor